Immix Biopharma, Inc. (Nasdaq: IMMX) recently announced a significant expansion of its clinical trial sites across the United States for the NEXICART-2 study, focusing on relapsed/refractory AL Amyloidosis. This expansion aims to provide broader patient access to innovative therapy options and
MSD, also known as Merck in North America, has taken a significant step to enhance its therapeutic portfolio by investing $1.3 billion in the acquisition of CN201 from Curon Biopharmaceutical. The investigational bispecific antibody is poised to change the landscape of treatments for B-cell
The biopharmaceutical industry is in a state of flux, marked by the FDA's scrutiny of immunotherapy drugs, financial challenges faced by biotech startups, and promising advancements in vaccine development and obesity treatments. As regulatory, operational, and market dynamics evolve, companies
The transformative journey of eXmoor Pharma has reached a pivotal moment with the recent acquisition of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This milestone
Eli Lilly's groundbreaking medication, tirzepatide, also known as Mounjaro and Zepbound, has demonstrated remarkable success in reducing the risk of Type 2 diabetes and promoting weight loss. The results from the extensive Phase 3 trial, named SURMOUNT-1, have sparked significant interest and
Grail, a leading player in the cancer detection industry, is making a significant cut to its workforce, laying off approximately 350 employees, which represents about 25% of its total workforce. This substantial reduction is part of a major restructuring effort aimed at refocusing the company’s r
